- Home
- CC vs GLPG Comparison
CC vs GLPG Comparison
Compare CC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CC | GLPG |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CC | GLPG |
|---|---|---|
| Price | $11.77 | $32.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $17.00 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.1M | 84.7K |
| Earning Date | 02-17-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,837,000,000.00 | $336,643,201.00 |
| Revenue This Year | $3.34 | $1.76 |
| Revenue Next Year | $4.15 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.03 | ★ 10.31 |
| 52 Week Low | $9.13 | $22.36 |
| 52 Week High | $20.12 | $37.78 |
Technical Indicators
Market Signals| Indicator | CC | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 56.87 |
| Support Level | $11.73 | $32.65 |
| Resistance Level | $12.06 | $33.37 |
| Average True Range (ATR) | 0.44 | 0.61 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 12.31 | 73.16 |
Price Performance
Historical ComparisonAbout CC Chemours Company (The)
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.